1. Home
  2. DLNG vs SPRO Comparison

DLNG vs SPRO Comparison

Compare DLNG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$3.81

Market Cap

136.4M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.50

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLNG
SPRO
Founded
2013
2013
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.4M
136.7M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
DLNG
SPRO
Price
$3.81
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
38.5K
248.8K
Earning Date
11-20-2025
11-13-2025
Dividend Yield
5.36%
N/A
EPS Growth
30.14
N/A
EPS
1.29
N/A
Revenue
$158,275,000.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.37
N/A
P/E Ratio
$2.90
N/A
Revenue Growth
4.34
N/A
52 Week Low
$3.18
$0.51
52 Week High
$5.51
$3.22

Technical Indicators

Market Signals
Indicator
DLNG
SPRO
Relative Strength Index (RSI) 48.94 61.53
Support Level $3.79 $2.26
Resistance Level $3.79 $2.66
Average True Range (ATR) 0.10 0.08
MACD -0.02 0.03
Stochastic Oscillator 25.35 66.23

Price Performance

Historical Comparison
DLNG
SPRO

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: